Kinetic and affinity limits on antibodies produced during immune responses. - Wikidata - awgldk - TriplyDB

Kinetic and affinity limits on antibodies produced during immune responses.

Kinetic and affinity limits on antibodies produced during immune responses.

http://www.wikidata.org/entity/Q34598643

about

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells Electrophilic affibodies forming covalent bonds to protein targets Antibody promiscuity: Understanding the paradigm shift in antigen recognition The structural basis of repertoire shift in an immune response to phosphocholine Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation Reconciling the Structural Attributes of Avian Antibodies Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory Association rate constants of ras-effector interactions are evolutionarily conserved High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.In vitro evolution of a T cell receptor with high affinity for peptide/MHC.Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space.Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.Antibodies as therapeutic agents: vive la renaissance!Isolation of anti-CD22 Fv with high affinity by Fv display on human cells.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 Back to the future: recombinant polyclonal antibody therapeutics.Mammalian cell display for antibody engineering In vitro antibody affinity maturation targeting germline hotspots Display and selection of scFv antibodies on HEK-293T cells.High-affinity lamprey VLRA and VLRB monoclonal antibodies Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 Computational design of antibody-affinity improvement beyond in vivo maturation Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands The protein-protein interface evolution acts in a similar way to antibody affinity maturation.Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides Fundamental aspects of protein-protein association kinetics Multidimensional analysis of the frequencies and rates of cytokine secretion from single cells by quantitative microengraving.Association and dissociation kinetics of anti-hen egg lysozyme monoclonal antibodies HyHEL-5 and HyHEL-10 Kinetics of association of anti-lysozyme monoclonal antibody D44.1 and hen-egg lysozyme.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment Comparative analyses of immunoglobulin genes: surprises and portents.Profiling antibody responses by multiparametric analysis of primary B cells.The influence of antibody fragment format on phage display based affinity maturation of IgG.Llama nanoantibodies with therapeutic potential against human norovirus diarrhea.

P2860

Q21089590-BAE860DA-1FB9-41DE-80F6-BE1856E7BCEE Q24594878-DAEFF8C4-311F-44D6-891B-6B4E4ED749B2 Q24651974-A5EED8EB-B82B-4430-A8E8-917D28EB40B8 Q26801316-8B42A05A-C299-4B1C-A325-5DB4345BC241 Q27624954-831D6226-9E23-4FA7-91D7-A4ACD83AF2CF Q27652612-6DA69BD2-AB09-441A-8588-5EA574559428 Q27683425-123DEEF8-D350-43E1-8CB9-98A987D0E79D Q28071559-6126DD11-E74D-4B2F-9674-1BF4B03B6638 Q28474223-087EC008-D8A5-4106-9661-EF60847C7EF8 Q28480982-C033BCD1-E289-40A7-8767-89746B5E613C Q30769483-564F1677-E34F-4C98-A98D-6B13761BD7FC Q30861962-6D5E30A0-8299-4DF2-BE81-546533D3A244 Q30923970-9D06DA80-D924-4608-9111-43DE4FDAF9F1 Q31149925-D5BDE29B-9010-4302-98CB-5BCB20F6B1D6 Q31949891-E2CF30C2-A813-40FC-869C-DDD60D8B1ADE Q32026627-0556FC2F-183D-4C1E-998A-5F8703797FC7 Q33193524-8E6D833A-789A-48EC-84A7-CE8A929FCA2D Q33246226-AA3E5DBC-4C8B-497C-89FF-B4BD6D9246EB Q33374701-4172CDDA-8708-4BDC-BD45-E322CA78CA1E Q33412776-3D48D81B-F2C1-4211-8626-B8A5FC7E12FD Q33413791-2F1D3975-134C-4E03-BC6B-3384A2D781F1 Q33413796-D1EA65F1-8EC9-4B85-9500-5E624F44FD50 Q33474388-823F7A5F-5198-4187-BDFF-243CF4BDE4A4 Q33485795-6D353FFE-8DAE-4B9E-BD4A-DC0F527F3430 Q33558279-C4641BC6-5D9E-43DB-A775-F7FC649F9FE7 Q33576857-5AC74F35-2B08-4072-82C1-AAA6267B2D29 Q33657353-C2E4274F-857E-4105-9134-32EC8D53A161 Q33662167-851B083C-A332-4296-B4D0-A0BAA2E9199E Q33867137-F5AF4D35-D366-4AD3-B687-EFB72D004485 Q33893739-0F7D696D-265C-495E-8B83-8494E0F9ED35 Q34109159-062E6622-10FD-4006-AE1B-11BB390056AA Q34167645-09617AC8-2142-4DC9-BD5B-3D5821055C74 Q34174497-E5FCF49B-7723-4057-B94F-4326441F5F8E Q34225659-BEF621B5-9C8D-4DB0-A07A-842FACB516E5 Q34244499-F4B22676-12BD-4FC8-9790-0E0B148E8BD9 Q34675779-70787A61-F96F-4FD9-A194-4508541F3F21 Q34810278-967C4AF4-CA39-4A73-8E44-057F44B11572 Q34878648-FEADA10E-0721-4801-8A6A-CBD91E05FBBF Q35050036-F3710375-02A3-4B8C-BD11-3D6F65F31CD7 Q35744232-AFD8548A-0292-4292-80BC-8BF77838F7F1

P2860

Kinetic and affinity limits on antibodies produced during immune responses.

http://www.wikidata.org/entity/Q34598643

description

1995 nî lūn-bûn

@nan

1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年学术文章

@wuu

1995年学术文章

@zh-cn

1995年学术文章

@zh-hans

1995年学术文章

@zh-my

1995年学术文章

@zh-sg

1995年學術文章

@yue

name

Kinetic and affinity limits on antibodies produced during immune responses.

@ast

Kinetic and affinity limits on antibodies produced during immune responses.

@en

Kinetic and affinity limits on antibodies produced during immune responses.

@nl

type

label

Kinetic and affinity limits on antibodies produced during immune responses.

@ast

Kinetic and affinity limits on antibodies produced during immune responses.

@en

Kinetic and affinity limits on antibodies produced during immune responses.

@nl

prefLabel

Kinetic and affinity limits on antibodies produced during immune responses.

@ast

Kinetic and affinity limits on antibodies produced during immune responses.

@en

Kinetic and affinity limits on antibodies produced during immune responses.

@nl

P1433

Q34598643-3A8ADDAD-76D0-427F-878F-D7F833D90252

P1476

Q34598643-CB0647FF-EE87-4FCB-B731-4D70C151664E

P2093

Q34598643-56337B68-F5B6-44E3-8634-195DFB0F746C

Q34598643-D319A345-FE67-4CCD-B6B3-2AE9F76072A4

P2860

Q34598643-033B8FD3-1B14-48D2-A8C1-5662D9DE9615

Q34598643-047231DE-1D15-4B48-9014-9B784505F31B

Q34598643-05101202-E33D-4561-A858-EF2C676D0857

Q34598643-0EFB8DF8-D24D-435F-8E0C-A74F8F3D1737

Q34598643-1E9826DD-AB37-4AF1-836D-3EC42E0ED700

Q34598643-1FF3693F-1BD2-4D6D-A269-43BD5E902207

Q34598643-333A9C03-031A-46A7-AF3F-7A70AA791DB7

Q34598643-37A07E80-28BB-4DEB-ADC3-886030EC2F7B

Q34598643-4AAB6F0D-FE8B-45EA-A0D4-7794F5DD6A18

Q34598643-53457636-979E-42E8-B07C-1BB170B79DAE

P304

Q34598643-2688BEE6-6F34-4B08-A058-028CF7401E03

P31

Q34598643-07F563ED-7E65-44F7-998B-767F029CBB2E

P356

Q34598643-C3BA74FC-BD4D-4D03-BC7B-75B0E055372B

P407

Q34598643-609FFBA6-60DE-4302-83EA-8D59335A386A

P433

Q34598643-49BC0BED-217C-4768-91B8-BD07FECE882A

P478

Q34598643-D62BC571-D318-4F69-91F9-172FBB9856A2

P577

Q34598643-441E3E45-7169-4801-9A11-654292C8E595

P5875

Q34598643-D813F623-4739-430A-83AE-91AF69925FB6

P698

Q34598643-D3785A49-E0F7-4EA2-B55B-67E9697BD519

P921

Q34598643-87255870-E01A-4753-A651-F6A54C014916

P932

Q34598643-B789E023-906B-4AC2-A551-BD7F27202318

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Kinetic and affinity limits on antibodies produced during immune responses.

@en

P2093

H N Eisen

http://www.w3.org/2001/XMLSchema#string

J Foote

http://www.w3.org/2001/XMLSchema#string

P2860

Three-dimensional structure of murine anti-p-azophenylarsonate Fab 36-71. 1. X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten

Mass and molecular composition of vesicular stomatitis virus: a scanning transmission electron microscopy analysis.

Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group

Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

Somatic evolution of variable region structures during an immune response.

The relative affinity of antibodies synthesized in the secondary response.

Early onset of somatic mutation in immunoglobulin VH genes during the primary immune response

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. III. The kinetics of V region mutation and selection in germinal center B cells

Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region.

P304

1254-1256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.92.5.1254

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

1995-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15321192

http://www.w3.org/2001/XMLSchema#string

P698

7877964

http://www.w3.org/2001/XMLSchema#string

P921

P932

42497

http://www.w3.org/2001/XMLSchema#string